Intravenous Immunoglobulin Therapy in Vasculitis: Speculation or Evidence?
- 1 January 2005
- journal article
- review article
- Published by Springer Nature in Clinical Reviews in Allergy & Immunology
- Vol. 29 (3) , 237-246
Abstract
Initially, intravenous immunoglobulins (IVIgs) were used as replacement therapy in primary and secondary antibody-deficiency syndromes. The clinical use of IVIg has been extended during the past decade to a wide variety of clinical conditions, such as infectious processes, neuroimmunological diseases, and different systemic autoimmune diseases. The mode of action of IVIg is complex, involving modulation of the Fc receptors, interference with the complement and cytokine network, and effects on the activation and differentiation of T-and B-cells. Kawasaki disease (KD) was one of the first diseases within the group of primary vasculitides in which IVIg were used. Today, there is a clear evidence of benefit for IVIg in the treatment of coronary artery abnormalities related to KD. Subsequently, various reports have suggested a beneficial effect in other vasculitides; however, there are few data from controlled studies. For antineutrophil cytoplasmic antibody-associated vasculitis (AAV) one placebo-controlled and several open-label studies have shown a beneficial effect on the disease activity in patients with Wegener’s granulomatosis or microscopic polyangiitis refractory to standard therapy with prednisone and cyclophosphamide. For other vasculitides, such as polyarteritis nodosa or Henoch-Schonlein purpura, only case reports have described an inhibition of a disease progression by IVIg so far. However, the effect was partly only temporary. In conclusion, KD and AAV are the only vasculitides with a definite beneficial use of IVIg. For other vasculitides, the efficacy of IVIg has not been proven properly but may be useful in single cases.Keywords
This publication has 48 references indexed in Scilit:
- Immunomodulation of Autoimmune and Inflammatory Diseases with Intravenous Immune GlobulinNew England Journal of Medicine, 2001
- The B Cell Superantigen-like Interaction of Intravenous Immunoglobin (IVIG) with Fab Fragments of VH 3-23 and 3-30/3-30.5 Germline Gene Origin Cloned from a Patient with Kawasaki Disease Is Enhanced after IVIG TherapyClinical Immunology, 2001
- Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activityQJM: An International Journal of Medicine, 2000
- Marked improvement of Churg-Strauss vasculitis with intravenous gammaglobulins.Southern Medical Journal, 1999
- The Prevention of Coronary Artery Aneurysm in Kawasaki Disease: A Meta-analysis on the Efficacy of Aspirin and Immunoglobulin TreatmentPediatrics, 1995
- Pooled Intravenous Immunoglobulin in the Management of Systemic Vasculitis1993
- Kawasaki diseaseCurrent Opinion in Rheumatology, 1993
- ANTIGENIC RECOGNITION BY INTRAVENOUS GAMMA-GLOBULIN OF SELECTED BACTERIA ISOLATED FROM THROATS OF PATIENTS WITH KAWASAKI SYNDROME1990
- HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR KAWASAKI DISEASEThe Lancet, 1984
- [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children].1967